Giovannoni G, et al. Treatment outcomes of daclizumab in patients at high risk of transitioning to secondary progressive multiple sclerosis in DECIDE. EAN 2107, O2113.
Rabobank investeert 3 miljoen in ALS Investment Fund
nov 2017 | Neuro-musculair
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen